• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动态对比增强磁共振成像定量参数在肝脏肿块定性诊断中的评估

Evaluation of quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging in qualitative diagnosis of hepatic masses.

作者信息

Chen Jingjing, Si Youjiao, Zhao Kaikai, Shi Xianglong, Bi Weiqun, Liu Shi-En, Hua Hui

机构信息

Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong Province, China.

Department of Radiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, Shandong Province, China.

出版信息

BMC Med Imaging. 2018 Dec 27;18(1):56. doi: 10.1186/s12880-018-0299-8.

DOI:10.1186/s12880-018-0299-8
PMID:30587152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6307244/
Abstract

BACKGROUND

To explore the value of parameters of multiphase dynamic contrast-enhanced magnetic resonance imaging (MDCE-MRI) in the qualitative diagnosis of hepatic masses.

METHODS

Eighty patients with hepatic masses were retrospectively analyzed. All the patients underwent MDCE-MRI at 3.0 T MR before treatment. Mean enhancement time (MET), positive enhancement integral (PEI), a maximum slope of increase (MSI), and a maximum slope of decrease (MSD) were measured.

RESULTS

There were significant differences between benign and malignant hepatic masses with respect to MET, PEI, and MSI values. The PEI and MSI values between hemangiomas, hepatocellular carcinomas (HCCs), cholangiocarcinomas, and metastatic tumors had significant differences. The MSD value between metastatic tumors, HCCs, and hemangiomas were significantly different. The area under the curve (AUC) values of the receiver operator characteristic curves for MET, PEI, and MSI were 0.70, 0.72, and 0.80, respectively. The specificity of MET, PEI, and MSI were all 77%, and the sensitivities of MSI was the highest, of which was 82.40%. Logistic regression analysis showed the regression equation to be P = 1/[1 + e], and taking the Youden index maximum points as a diagnostic point was 0.2946.

CONCLUSION

Some parameters of MDCE-MRI have significant roles in differentiating hepatic masses.

摘要

背景

探讨多期动态对比增强磁共振成像(MDCE-MRI)参数在肝脏肿块定性诊断中的价值。

方法

回顾性分析80例肝脏肿块患者。所有患者在治疗前行3.0 T MR的MDCE-MRI检查。测量平均强化时间(MET)、强化阳性积分(PEI)、最大上升斜率(MSI)和最大下降斜率(MSD)。

结果

良性和恶性肝脏肿块在MET值、PEI值和MSI值方面存在显著差异。血管瘤、肝细胞癌(HCC)、胆管癌和转移瘤之间的PEI值和MSI值存在显著差异。转移瘤、HCC和血管瘤之间的MSD值有显著差异。MET、PEI和MSI的受试者操作特征曲线的曲线下面积(AUC)值分别为0.70、0.72和0.80。MET、PEI和MSI的特异性均为77%,MSI的敏感性最高,为82.40%。Logistic回归分析显示回归方程为P = 1/[1 + e],以约登指数最大值点作为诊断点为0.2946。

结论

MDCE-MRI的一些参数在鉴别肝脏肿块方面具有重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/d1c9c37094bd/12880_2018_299_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/9d2414cfddd2/12880_2018_299_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/b415daee4e68/12880_2018_299_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/ba62d1859046/12880_2018_299_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/d1c9c37094bd/12880_2018_299_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/9d2414cfddd2/12880_2018_299_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/b415daee4e68/12880_2018_299_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/ba62d1859046/12880_2018_299_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cb/6307244/d1c9c37094bd/12880_2018_299_Fig4_HTML.jpg

相似文献

1
Evaluation of quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging in qualitative diagnosis of hepatic masses.动态对比增强磁共振成像定量参数在肝脏肿块定性诊断中的评估
BMC Med Imaging. 2018 Dec 27;18(1):56. doi: 10.1186/s12880-018-0299-8.
2
Utility of semiquantitative parameters to differentiate benign and malignant focal hepatic lesions.半定量参数在鉴别良恶性局灶性肝病变中的作用。
Clin Imaging. 2013 Jul-Aug;37(4):692-6. doi: 10.1016/j.clinimag.2013.01.012. Epub 2013 Feb 27.
3
High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions.钆塞酸增强肝脏磁共振成像上表现为“假性廓清”的高流量血管瘤与高血供肝细胞癌:扩散加权成像在小病灶鉴别诊断中的价值
Clin Radiol. 2017 Mar;72(3):247-254. doi: 10.1016/j.crad.2016.09.020. Epub 2016 Oct 24.
4
Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.钆塞酸二钠增强MRI的减影图像:对肝细胞癌高危患者局灶性肝病变诊断性能的影响
AJR Am J Roentgenol. 2017 Sep;209(3):584-591. doi: 10.2214/AJR.16.17211. Epub 2017 Jun 13.
5
Application of acoustic radiation force impulse imaging for the evaluation of focal liver lesion elasticity.声辐射力脉冲成像技术在评估局灶性肝病变弹性中的应用。
Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):165-70. doi: 10.1016/s1499-3872(13)60027-2.
6
Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.CT 和钆塞酸增强磁共振成像上肝肉瘤样癌的影像学特征。
Abdom Radiol (NY). 2017 May;42(5):1424-1433. doi: 10.1007/s00261-016-1038-7.
7
Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance.在钆塞酸增强磁共振成像的肝细胞癌增强模式中添加辅助特征可提高诊断性能。
Abdom Radiol (NY). 2018 Sep;43(9):2309-2320. doi: 10.1007/s00261-018-1480-9.
8
Value of Perfusion Parameters for Differentiating Hepatocellular Carcinoma and Liver Metastasis With Hypervascularity and a Normal Hepatic Background on Contrast-Enhanced Ultrasound Imaging.超声造影增强成像背景正常肝实质中高血供肝细胞癌与肝转移瘤的灌注参数鉴别价值。
J Ultrasound Med. 2019 Oct;38(10):2601-2608. doi: 10.1002/jum.14957. Epub 2019 Jan 30.
9
Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Distinguishing Hepatocellular Carcinoma From Cholangiocarcinoma in Pre-Liver Transplantation Evaluation.
Transplant Proc. 2016 May;48(4):1041-4. doi: 10.1016/j.transproceed.2015.11.026.
10
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.在一项多中心回顾性研究中,1006 个结节的对比超声 LI-RADS LR-5 可识别肝硬化中的肝细胞癌。
J Hepatol. 2018 Mar;68(3):485-492. doi: 10.1016/j.jhep.2017.11.007. Epub 2017 Nov 11.

引用本文的文献

1
A nomogram based on quantitative MR signal intensity predicts early response to combined systemic treatment in patients with hepatocellular carcinoma.基于定量磁共振信号强度的列线图可预测肝细胞癌患者对联合全身治疗的早期反应。
Front Oncol. 2025 Mar 13;15:1527108. doi: 10.3389/fonc.2025.1527108. eCollection 2025.
2
Diagnostic Values of the Liver Imaging Reporting and Data System in the Detection and Characterization of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.肝脏影像报告和数据系统在肝细胞癌检测与特征描述中的诊断价值:一项系统评价和Meta分析
Cureus. 2023 Mar 13;15(3):e36082. doi: 10.7759/cureus.36082. eCollection 2023 Mar.
3

本文引用的文献

1
Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.甲胎蛋白与异常凝血酶原联合检测在中国肝细胞癌患者诊断中的临床应用:一项针对1153名受试者的多中心病例对照研究
Biosci Trends. 2014 Oct;8(5):266-73. doi: 10.5582/bst.2014.01116.
2
Contrast-enhanced MR angiography of the abdomen with highly accelerated acquisition techniques.腹部高加速采集技术的磁共振血管造影增强。
Radiology. 2011 Nov;261(2):587-97. doi: 10.1148/radiol.11110242. Epub 2011 Sep 7.
3
Hepatic perfusion disorder associated with focal liver lesions: contrast-enhanced US patterns--correlation study with contrast-enhanced CT.
Role of MRI-Derived Radiomics Features in Determining Degree of Tumor Differentiation of Hepatocellular Carcinoma.
MRI衍生的影像组学特征在确定肝细胞癌肿瘤分化程度中的作用
Diagnostics (Basel). 2022 Sep 30;12(10):2386. doi: 10.3390/diagnostics12102386.
4
Current Imaging Diagnosis of Hepatocellular Carcinoma.肝细胞癌的当前影像诊断
Cancers (Basel). 2022 Aug 18;14(16):3997. doi: 10.3390/cancers14163997.
5
Quantitative magnetic resonance imaging for focal liver lesions: bridging the gap between research and clinical practice.定量磁共振成像在肝脏局灶性病变中的应用:弥合研究与临床实践之间的差距。
Br J Radiol. 2021 Jun 1;94(1122):20210220. doi: 10.1259/bjr.20210220. Epub 2021 May 14.
肝脏灌注异常与局灶性肝脏病变相关:超声造影与增强 CT 对比的相关性研究。
Radiology. 2011 Jul;260(1):274-81. doi: 10.1148/radiol.11101454. Epub 2011 Apr 5.
4
Celiac disease: evaluation with dynamic contrast-enhanced MR imaging.腹腔疾病:动态对比增强磁共振成像的评估。
Radiology. 2010 Sep;256(3):783-90. doi: 10.1148/radiol.10092160. Epub 2010 Jul 27.
5
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.钆塞酸增强磁共振成像在鉴别 < 或 = 2cm 直径的小肝癌和动脉期增强假性病灶中的应用:特别强调肝胆期成像。
Invest Radiol. 2010 Feb;45(2):96-103. doi: 10.1097/RLI.0b013e3181c5faf7.
6
Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model.肝转移瘤:采用双输入双室示踪剂动力学模型在动态对比增强磁共振成像中对灌注参数进行体内评估。
Radiology. 2008 Oct;249(1):307-20. doi: 10.1148/radiol.2483071958. Epub 2008 Aug 11.
7
Focal liver masses: enhancement patterns on contrast-enhanced images--concordance of US scans with CT scans and MR images.肝脏局灶性肿块:对比增强图像上的强化模式——超声扫描与CT扫描及磁共振图像的一致性
Radiology. 2007 Jan;242(1):162-74. doi: 10.1148/radiol.2421051006. Epub 2006 Nov 7.
8
Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.肝硬化中的肝细胞癌:钆和超顺磁性氧化铁增强T1加权磁共振成像的强化模式
Radiology. 2005 Nov;237(2):520-8. doi: 10.1148/radiol.2372041183. Epub 2005 Sep 28.
9
Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging.肝脏局灶性病变:三维对比增强梯度回波磁共振成像强化模式分析的诊断价值
Radiographics. 2005 Sep-Oct;25(5):1299-320. doi: 10.1148/rg.255045180.
10
Epidemiology and natural history of hepatocellular carcinoma.肝细胞癌的流行病学与自然史
Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23. doi: 10.1016/j.bpg.2004.10.004.